Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)

NCT05705401 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05705401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05705401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 19, 2023
Completion date
February 1, 2037
Enrollment
1,300 (estimated)
Sites
418

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer